Home › Companies › CYTOMX THERAPEUTICS INC. › 2023-2024
At CYTOMX THERAPEUTICS INC.'s shareholder meeting held May 15, 2024, in the 2023-2024 proxy season, 51 asset managers reported how they voted on 6 ballot items in their SEC Form N-PX filings, covering 223 separate fund positions. On the most widely held item on that ballot — To approve, on a nonbinding advisory basis, the compensation of the Company's named executive… — CYTOMX THERAPEUTICS INC.'s filing reports the proposal as approved, with 93% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: CYTOMX THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 17, 2024.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and CYTOMX THERAPEUTICS INC.’s Form 8-K, filed May 17, 2024 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of May 15, 2024: 6 items on CYTOMX THERAPEUTICS INC.’s Form 8-K, filed May 17, 2024: 3 approved · 3 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2023-2024 2025-2026
Explore CYTOMX THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are CYTOMX THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 17, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Alan Ashworth, Ph.D., FRS | 28,770,373 | 514,091 | 79,486 | -- | 17,554,723 | 98% | Not verified | — |
| Elect Director: James R. Meyers | 28,970,141 | 324,310 | 69,499 | -- | 17,554,723 | 99% | Not verified | — |
| Elect Director: Halley Gilbert | 24,008,423 | 5,271,685 | 83,842 | -- | 17,554,723 | 82% | Not verified | — |
| 2. The selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024 | 46,522,474 | 369,346 | 26,853 | -- | -- | 99.2% | Approved | — |
| 3. Of an amendment to the Company's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 150,000,000 shares to 300,000,000 shares | 42,707,436 | 3,211,496 | 999,741 | -- | -- | 93% | Approved | — |
| 4. On a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, pursuant to the compensation disclosure rules of the SEC | 27,396,411 | 1,905,835 | 61,704 | -- | 17,554,723 | 93% | Approved | — |
Source: CYTOMX THERAPEUTICS INC., Form 8-K, filed with the SEC on May 17, 2024 — read the filing on EDGAR.
Each item below shows how the 51 asset managers that disclosed a CYTOMX THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: To elect three directors with terms to expire at the 2027 Annual Meeting of Stockholders: Alan Ashworth, Ph.D.
CYTOMX THERAPEUTICS INC.’s own tally for this item (“Elect Director: Alan Ashworth, Ph.D., FRS”): 28,770,373 for, 514,091 against, per its Form 8-K filed May 17, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 12 asset managers below reported 5,861,993 for, 443,224 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,834,564 | 0 | 0 | 0 | For |
| Fidelity | 497,639 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 443,224 | 0 | 0 | Against |
| ETF Opportunities Trust | 300,105 | 0 | 0 | 0 | For |
| BlackRock | 144,800 | 0 | 0 | 0 | For |
| Managed Portfolio Series | 41,458 | 0 | 0 | 0 | For |
| Charles Schwab | 24,817 | 0 | 0 | 0 | For |
| Equitable | 11,022 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 4,500 | 0 | 0 | 0 | For |
| Russell Investments | 1,510 | 0 | 0 | 0 | For |
| John Hancock | 1,192 | 0 | 0 | 0 | For |
| Guggenheim | 386 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
82% Majority: yes · of votes cast
Description as filed by funds: To elect three directors with terms to expire at the 2027 Annual Meeting of Stockholders: Halley Gilbert
CYTOMX THERAPEUTICS INC.’s own tally for this item (“Elect Director: Halley Gilbert”): 24,008,423 for, 5,271,685 against, per its Form 8-K filed May 17, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 82% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 12 asset managers below reported 5,789,640 for, 515,577 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,834,564 | 0 | 0 | 0 | For |
| Fidelity | 497,639 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 443,224 | 0 | 0 | Against |
| ETF Opportunities Trust | 300,105 | 0 | 0 | 0 | For |
| BlackRock | 144,800 | 0 | 0 | 0 | For |
| Managed Portfolio Series | 0 | 41,458 | 0 | 0 | Against |
| Charles Schwab | 0 | 24,817 | 0 | 0 | Against |
| Equitable | 11,022 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 0 | 4,500 | 0 | 0 | Against |
| Russell Investments | 1,510 | 0 | 0 | 0 | For |
| John Hancock | 0 | 1,192 | 0 | 0 | Against |
| Guggenheim | 0 | 386 | 0 | 0 | Against |
Combines 3 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: To elect three directors with terms to expire at the 2027 Annual Meeting of Stockholders: James R. Meyers
CYTOMX THERAPEUTICS INC.’s own tally for this item (“Elect Director: James R. Meyers”): 28,970,141 for, 324,310 against, per its Form 8-K filed May 17, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 12 asset managers below reported 6,305,217 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,834,564 | 0 | 0 | 0 | For |
| Fidelity | 497,639 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 443,224 | 0 | 0 | 0 | For |
| ETF Opportunities Trust | 300,105 | 0 | 0 | 0 | For |
| BlackRock | 144,800 | 0 | 0 | 0 | For |
| Managed Portfolio Series | 41,458 | 0 | 0 | 0 | For |
| Charles Schwab | 24,817 | 0 | 0 | 0 | For |
| Equitable | 11,022 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 4,500 | 0 | 0 | 0 | For |
| Russell Investments | 1,510 | 0 | 0 | 0 | For |
| John Hancock | 1,192 | 0 | 0 | 0 | For |
| Guggenheim | 386 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
93% Approved · of votes cast
Description as filed by funds: To approve an amendment to our Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 150,000,000 shares to 300,000,000 shares;
CYTOMX THERAPEUTICS INC.’s own tally for this item (“3. Of an amendment to the Company's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 150,000,000 shares to 300,000,000 shares”): 42,707,436 for, 3,211,496 against — passed, per its Form 8-K filed May 17, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved of an amendment to the Company's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 150,000,000 shares to 300,000,000 shares.”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 12 asset managers below reported 6,305,217 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,834,564 | 0 | 0 | 0 | For |
| Fidelity | 497,639 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 443,224 | 0 | 0 | 0 | For |
| ETF Opportunities Trust | 300,105 | 0 | 0 | 0 | For |
| BlackRock | 144,800 | 0 | 0 | 0 | For |
| Managed Portfolio Series | 41,458 | 0 | 0 | 0 | For |
| Charles Schwab | 24,817 | 0 | 0 | 0 | For |
| Equitable | 11,022 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 4,500 | 0 | 0 | 0 | For |
| Russell Investments | 1,510 | 0 | 0 | 0 | For |
| John Hancock | 1,192 | 0 | 0 | 0 | For |
| Guggenheim | 386 | 0 | 0 | 0 | For |
Combines 7 wordings of this item as funds reported it.
93% Approved · of votes cast
Description as filed by funds: To approve, on a nonbinding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement accompanying this Notice of Annual Meeting of Stockholders; and
CYTOMX THERAPEUTICS INC.’s own tally for this item (“4. On a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, pursuant to the compensation disclosure rules of the SEC”): 27,396,411 for, 1,905,835 against — passed, per its Form 8-K filed May 17, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, pursuant to the compensation disclosure rules of the SEC.”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,834,564 | 0 | 0 | 0 | For |
| Fidelity | 497,639 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 443,224 | 0 | 0 | Against |
| ETF Opportunities Trust | 300,105 | 0 | 0 | 0 | For |
| BlackRock | 144,800 | 0 | 0 | 0 | For |
| Managed Portfolio Series | 41,458 | 0 | 0 | 0 | For |
| Charles Schwab | 24,817 | 0 | 0 | 0 | For |
| Equitable | 11,022 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 4,500 | 0 | 0 | 0 | For |
| Russell Investments | 1,510 | 0 | 0 | 0 | For |
| John Hancock | 1,192 | 0 | 0 | 0 | For |
| Guggenheim | 386 | 0 | 0 | 0 | For |
Fund voting reports, all 12 managers: 5,861,993 for, 443,224 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BVF INC/IL | 6,595,801 | 0 | 0 | 0 | For |
| ORBIMED ADVISORS LLC | 3,544,578 | 0 | 0 | 0 | For |
| Ensign Peak Advisors, Inc | 975,542 | 0 | 0 | 0 | For |
| ACADIAN ASSET MANAGEMENT LLC | 920,306 | 0 | 0 | 0 | For |
| Renaissance | 840,914 | 0 | 0 | 0 | For |
| Laurion Capital Management LP | 764,187 | 0 | 0 | 0 | For |
| Bronte Capital Management Pty Ltd. | 596,644 | 0 | 0 | 0 | For |
| BlackRock | 588,432 | 0 | 0 | 0 | For |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 523,847 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 465,739 | 0 | 0 | 0 | For |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0 | 443,224 | 0 | 0 | Against |
| Goldman Sachs | 292,562 | 0 | 0 | 0 | For |
| Connor, Clark & Lunn Investment Management Ltd. | 275,593 | 0 | 0 | 0 | For |
| Newton Investment Management North America, LLC | 0 | 234,970 | 0 | 0 | Against |
| Clearline Capital LP | 178,515 | 0 | 0 | 0 | For |
| Two Sigma | 160,399 | 0 | 0 | 0 | For |
| Fidelity | 116,536 | 0 | 0 | 0 | For |
| Northern Trust | 65,756 | 0 | 0 | 0 | For |
| State Street | 38,637 | 0 | 0 | 0 | For |
| West Coast Financial LLC | 36,163 | 0 | 0 | 0 | For |
| OMERS ADMINISTRATION Corp | 35,400 | 0 | 0 | 0 | For |
| BALYASNY ASSET MANAGEMENT L.P. | 31,446 | 0 | 0 | 0 | For |
| STIFEL NICOLAUS & CO INC \MO\ | 25,000 | 0 | 0 | 0 | For |
| Charles Schwab | 24,817 | 0 | 0 | 0 | For |
| Vanguard | 22,810 | 0 | 0 | 0 | For |
Institutional-manager reports, all 45 managers: 17,240,217 for, 678,194 against. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.2% Approved · of votes cast
Description as filed by funds: To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024;
CYTOMX THERAPEUTICS INC.’s own tally for this item (“2. The selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024”): 46,522,474 for, 369,346 against — passed, per its Form 8-K filed May 17, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024.”
Support: 99.2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 12 asset managers below reported 6,305,217 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,834,564 | 0 | 0 | 0 | For |
| Fidelity | 497,639 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 443,224 | 0 | 0 | 0 | For |
| ETF Opportunities Trust | 300,105 | 0 | 0 | 0 | For |
| BlackRock | 144,800 | 0 | 0 | 0 | For |
| Managed Portfolio Series | 41,458 | 0 | 0 | 0 | For |
| Charles Schwab | 24,817 | 0 | 0 | 0 | For |
| Equitable | 11,022 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 4,500 | 0 | 0 | 0 | For |
| Russell Investments | 1,510 | 0 | 0 | 0 | For |
| John Hancock | 1,192 | 0 | 0 | 0 | For |
| Guggenheim | 386 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 67,721,658 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 7.14% |
| 2 | Fidelity | 0.73% |
| 3 | BRIDGEWAY FUNDS INC | 0.65% |
| 4 | ETF Opportunities Trust | 0.44% |
| 5 | BlackRock | 0.21% |
| 6 | Managed Portfolio Series | 0.06% |
| 7 | Charles Schwab | 0.04% |
| 8 | Equitable | 0.02% |
| 9 | Blackstone Alternative Investment Funds | <0.01% |
| 10 | Russell Investments | <0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BVF INC/IL | 9.74% |
| 2 | ORBIMED ADVISORS LLC | 5.23% |
| 3 | Ensign Peak Advisors, Inc | 1.44% |
| 4 | ACADIAN ASSET MANAGEMENT LLC | 1.36% |
| 5 | Renaissance | 1.24% |
| 6 | Laurion Capital Management LP | 1.13% |
| 7 | Bronte Capital Management Pty Ltd. | 0.88% |
| 8 | BlackRock | 0.87% |
| 9 | JACOBS LEVY EQUITY MANAGEMENT, INC | 0.77% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 0.69% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| FMR (Fidelity) | — | 13F |
| Point72 Asset Management, L.P. | — | 13G |
| Venrock Healthcare Capital Partners III, L.P. | — | 13G |
| Longitude Capital Partners V, LLC | — | 13G |
| Vanguard Group | — | 13F |
| TANG CAPITAL MANAGEMENT, LLC | — | 13G |
| Biotechnology Value Fund | — | DEF14A |
| Sean A. McCarthy, D. Phil. | — | DEF14A |
| BlackRock | — | 13F |
| Renaissance Technologies | — | 13F |
Percentages above are of 67,721,658 shares outstanding, as reported by CYTOMX THERAPEUTICS INC. on its Form 10-K dated February 29, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from CYTOMX THERAPEUTICS INC.’s 10-K dated February 29, 2024. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
CYTOMX THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2025-2026.
proxyvotesnow.com, “CYTOMX THERAPEUTICS (CTMX) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/cytomx-therapeutics-inc/2024 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.